Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the therapeutic benefit and safety of subcutaneous Surovatamig monotherapy as consolidation therapy for adults with Chronic Lymphocytic Leukaemia CLL or Small Lymphocytic Lymphoma SLL who have unmutated Immunoglobulin Heavy Chain Variable IGHV. This Phase III global, randomized, open-label, multicenter study includes patients after first-line induction therapy. The study aims to compare Surovatamig treatment versus observation in this population. The study has two parts Dose Optimisation and Safety Run-in DOSRI and the Phase III part. During the DOSRI part, two different doses of Surovatamig are tested subcutaneously for 6 cycles of 28 days each to determine the recommended Phase III dose RP3D. In Phase III, participants are randomly assigned to receive the RP3D of Surovatamig as consolidation therapy for 6 cycles or to be observed for 24 weeks without active treatment. Participants will be assessed regularly with evaluations of adverse events, disease progression, and response to treatment. Laboratory tests will monitor blood levels of Surovatamig and the presence of anti-drug antibodies. The primary outcomes include progression-free survival and safety over up to 5 years. Participants may be followed long-term to monitor overall survival and treatment effects. The total study duration may extend to several years, with scheduled visits during treatment and observation periods.